MDP Photo

The mission of the Georgetown University Memory Disorders Program is to prevent and treat Alzheimer's disease and related dementias by conducting innovative research, educating and training healthcare professionals and the public on research advances, and offering state-of-the-art clinical care.

UPCOMING EVENTS
Kaiser health news discussion on living well with dementia

WHEN: Tuesday, February 13, 2018 from 12:30-2:00 p.m. ET

WHERE: Barbara Jordan Conference Center in the Kaiser Family Foundation offices at 1330 G. St. NW, Washington DC.

Click here to rsvp to dc event

Kaiser health news logo in white on a dark blue background

Dementia is one of the most challenging chronic conditions for individuals and their caregivers. More than 15 million family members in the U.S. provide care for people with dementia. Living well with this condition is important to both groups — and extremely difficult to achieve in practice.

Join Kaiser Health News on Tuesday, Feb. 13, from 12:30 to 2:00 p.m. ET for an informative and important discussion about improving care and services for people with dementia and supporting their caregivers. It’s an opportunity to learn from experts in the field about the challenges and difficulties facing the patient, the caregiver, the community and policymakers. Topics will include understanding the stages of dementia from a medical, social, psychological and environmental perspective (it’s not just memory loss); how to find help; how to manage difficult behaviors; and understanding medications for people with dementia. 

Please come, ask questions and share experiences.

Kaiser Health News’ “Navigating Aging” columnist Judith Graham will moderate a discussion with you and a panel of experts as we explore this issue.

Our panelists are:

  • Nancy A. Hodgson, Ph.D., RN, FAAN, University of Pennsylvania, an expert on dementia care and end-of-life care for people with dementia; 
  • Helen Kales, M.D., University of Michigan, a geriatric psychiatrist and expert on dementia care and mental health issues; 
  • Yvonne Latty, BFA, MA, a journalist and professor, who is dealing with her mother’s Alzheimer’s; and
  • Katie Maslow, MSW, Gerontological Society of America, an expert on improving care for people with dementia and supporting their caregivers.

Registration and lunch begin at 12:00 p.m.

The event in the Foundation's Washington, D.C. office is open to the public. Feel free to share with your contacts and colleagues.

RSVP TO DC EVENT
MDP IN THE NEWS

The Nilotinib for Alzheimer's disease trial is now enrolling participants. Take a look at a recent interview with Dr. Turner and contact us for more information.

WE ARE ON FACEBOOK

"Like" our facebook page to stay up to date on research findings and helpful information

JOIN OUR MAILING LIST!

Would you like to receive our Fall newsletter? Sign up here to receive our newsletter either in the mail or via email. We send out two newsletters a year to everyone on our mailing list and as well invitations to our yearly fall appreciation event.

Research Studies

Here are our research studies that are currently recruiting patients.

Title Sponsor
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4) ATRI/ Eli Lilly and Company

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Biogen

DOD-ADNI: A Study of Brain Aging in Vietnam War Veterans

ATRI

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects with Mild to Moderate Alzheimer’s Disease

Georgetown University

A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease

Acadia

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

ATRI

An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease (AMARANTH)

Eli Lilly & Co

A Randomized, Double-blind, Placebo-controlled, Two-cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease

Novartis

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort

ACRIN

Check out our Research section for more information on how to participate in our clinical trials.

Make a Donation

For information about how to make a tax-deductible contribution to the Memory Disorders Program, please click here.